引用本文:胡建国.瑞舒伐他汀与阿托伐他汀治疗冠心病的效果对比观察[J].中国临床新医学,2018,11(9):919-922.
【打印本页】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 115次   下载 128 本文二维码信息
码上扫一扫!
分享到: 微信 更多
瑞舒伐他汀与阿托伐他汀治疗冠心病的效果对比观察
胡建国
451200 河南,巩义市人民医院心血管内科
摘要:
[摘要] 目的 比较观察瑞舒伐他汀和阿托伐他汀治疗冠心病的临床效果。方法 选取2014-06~2016-09心内科收治的160例冠心病患者,随机分为观察组和对照组,每组80例。观察组给予瑞舒伐他汀治疗,对照组给予同等剂量的阿托伐他汀进行治疗,连续治疗12个月后,观察两组患者治疗前后的血脂水平、超敏C反应蛋白(hs-CRP)、同型半胱氨酸(Hcy)、颈动脉内膜-中膜厚度(IMT)水平和不良反应发生率。结果 两组患者治疗后TC、TG、LDL-C水平均降低,HDL-C水平均升高。观察组治疗后TC[(4.01±0.50)mmol/L]、TG[(1.44±0.49)mmol/L]、LDL-C[(1.95±0.32)mmol/L]、HDL-C[(1.79±0.14)mmol/L]相比于对照组[分别为(4.78±0.49)mmol/L、(1.69±0.41)mmol/L、(2.35±0.39)mmol/L、(1.15±0.11)mmol/L]差异有统计学意义(P<0.05)。治疗后观察组hs-CRP、Hcy、颈动脉IMT水平及不良反应发生率均低于对照组,差异有统计学意义(P<0.05)。结论 对于冠心病患者,相同剂量的瑞舒伐他汀的调脂效果优于阿托伐他汀,且不良反应发生率低于阿托伐他汀。
关键词:  瑞舒伐他汀  阿托伐他汀  冠心病  效果
DOI:10.3969/j.issn.1674-3806.2018.09.20
分类号:R 54
基金项目:
Comparison of rosuvastatin and atorvastatin in treatment of coronary heart disease
HU Jian-guo
Department of Cardiology, the People′s Hospital of Gongyi City, Henan 451200, China
Abstract:
[Abstract] Objective To compare and analyze the clinical effects of rosuvastatin and atorvastatin in the treatment of coronary heart disease. Methods 160 patients with coronary heart disease were selected in the Department of Cardiology of our hospital from June 2014 to September 2016 and were randomly divided into the observation group and the control group, with 80 cases in each group. The observation group was given rosuvastatin treatment, and the control group was given the same dose of atorvastatin for continuous 12 months. The levels of serum lipid, high sensitivity C reactive protein(hs-CRP), homocysteine(Hcy) and carotid intima-media thickness(IMT) were compared between the two groups before and after treatment. The incidence of adverse reactions was compared between the two groups after treatment. Results After treatment, the levels of TC, TG and LDL-C decreased, and the level of HDL-C increased in both of the two groups. The improvements of TC[(4.01±0.50)mmol/L], TG[(1.44±0.49)mmol/L], LDL-C[(1.95±0.32)mmol/L] and HDL-C[(1.79±0.14)mmol/L] in the observation group were better than those in the control group[(4.78±0.49)mmol/L, (1.69±0.41)mmol/L, (2.35±0.39)mmol/L and (1.15±0.11)mmol/L] after treatment(P<0.05). The levels of hs-CRP, Hcy, carotid artery IMT and the incidence of adverse reactions in the observation group were significantly lower than those in the control group after treatment(P<0.05). Conclusion For the patients with coronary heart disease, at the same dose, the lipid-lowering effect of rosuvastatin is superior to atorvastatin and the incidence of adverse reactions of rosuvastatin is lower than that of atorvastatin.
Key words:  Rosuvastatin  Atorvastatin  Coronary heart disease  Effect